BC Extra | Sep 19, 2017
Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
BC Extra | Aug 15, 2016
Company News

Management tracks

Antibody and cell therapy company Sorrento Therapeutics Inc. (NASDAQ:SNRE) hired Jerome Zeldis as CMO and president of clinical development. Zeldis was CMO of Celgene Corp. (NASDAQ:CELG) and CEO of its Celgene Global Health unit. Rare...
BC Extra | Jul 18, 2016
Company News

Management tracks

Cancer and neurology company e-Therapeutics plc (LSE:ETX) said Malcolm Young resigned as CEO and a director. The company is searching for a replacement. Gene therapy company Calimmune Inc. (Tucson, Ariz.) promoted Jeffrey Bartlett to CSO...
BioCentury | Jul 11, 2016
Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
BioCentury | May 23, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/20 cls Arbutus Biopharma Corp. (NASDAQ:ABUS) Chardan Capital Madhu Kumar New Sell -6% $4.08 Kumar initiated coverage with a $3.25...
BC Week In Review | May 16, 2016
Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015 , a biosimilar of Remicade...
BC Extra | May 10, 2016
Company News

Management tracks

Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott Rocklage, a director, CEO and promoted Chief...
BC Extra | Nov 11, 2015
Company News

Management tracks

Tauopathy therapeutic developer Asceneuron S.A. (Lausanne, Switzerland) appointed Hans Schikan chairman. Schikan is chairman of Complix N.V. (Diepenbeek, Belgium) and InteRNA Technologies B.V. (Nijmegen, the Netherlands) and previously was CEO of Prosensa Holding N.V. , which...
BC Week In Review | Sep 14, 2015
Company News

Bioceros, Epirus deal

Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) markets Simponi and Stelara to treat autoimmune diseases. Epirus would not disclose when the company plans to begin clinical testing for the acquired biosimilars. Bioceros B.V. , Utrecht, the...
BC Extra | Sep 10, 2015
Company News

Epirus nabs biosimilars in Bioceros takeout

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period. Epirus gains three preclinical candidates: BOW080, a biosimilar of...
Items per page:
1 - 10 of 41
BC Extra | Sep 19, 2017
Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
BC Extra | Aug 15, 2016
Company News

Management tracks

Antibody and cell therapy company Sorrento Therapeutics Inc. (NASDAQ:SNRE) hired Jerome Zeldis as CMO and president of clinical development. Zeldis was CMO of Celgene Corp. (NASDAQ:CELG) and CEO of its Celgene Global Health unit. Rare...
BC Extra | Jul 18, 2016
Company News

Management tracks

Cancer and neurology company e-Therapeutics plc (LSE:ETX) said Malcolm Young resigned as CEO and a director. The company is searching for a replacement. Gene therapy company Calimmune Inc. (Tucson, Ariz.) promoted Jeffrey Bartlett to CSO...
BioCentury | Jul 11, 2016
Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big...
BioCentury | May 23, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/20 cls Arbutus Biopharma Corp. (NASDAQ:ABUS) Chardan Capital Madhu Kumar New Sell -6% $4.08 Kumar initiated coverage with a $3.25...
BC Week In Review | May 16, 2016
Company News

Epirus biosimilars, hematology, cancer news

Epirus will reduce headcount by 40% to reprioritize its pipeline to focus exclusively on developing biosimilars for rare diseases. The company will suspend development of its Phase III-ready lead program BOW015 , a biosimilar of Remicade...
BC Extra | May 10, 2016
Company News

Management tracks

Metabolic company Arena Pharmaceuticals Inc. (NASDQ:ARNA) named Amit Munshi CEO and interim principal financial officer. He was president and CEO at Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS). Epirus named Scott Rocklage, a director, CEO and promoted Chief...
BC Extra | Nov 11, 2015
Company News

Management tracks

Tauopathy therapeutic developer Asceneuron S.A. (Lausanne, Switzerland) appointed Hans Schikan chairman. Schikan is chairman of Complix N.V. (Diepenbeek, Belgium) and InteRNA Technologies B.V. (Nijmegen, the Netherlands) and previously was CEO of Prosensa Holding N.V. , which...
BC Week In Review | Sep 14, 2015
Company News

Bioceros, Epirus deal

Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) markets Simponi and Stelara to treat autoimmune diseases. Epirus would not disclose when the company plans to begin clinical testing for the acquired biosimilars. Bioceros B.V. , Utrecht, the...
BC Extra | Sep 10, 2015
Company News

Epirus nabs biosimilars in Bioceros takeout

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) acquired biosimilars company Bioceros B.V. (Utrecht, the Netherlands) for $14.1 million in cash and stock to be paid over a one-year period. Epirus gains three preclinical candidates: BOW080, a biosimilar of...
Items per page:
1 - 10 of 41